• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

数字疗法:非酒精性脂肪性肝病的新兴新疗法。

Digital Therapeutics: Emerging New Therapy for Nonalcoholic Fatty Liver Disease.

机构信息

College of Nursing, Hangzhou Normal University, Zhejiang, China.

School of Public Health, Hangzhou Normal University, Zhejiang, China.

出版信息

Clin Transl Gastroenterol. 2023 Apr 1;14(4):e00575. doi: 10.14309/ctg.0000000000000575.

DOI:10.14309/ctg.0000000000000575
PMID:36854062
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10132718/
Abstract

The increased prevalence of nonalcoholic fatty liver disease (NAFLD) worldwide is particularly worrisome, as no medication has been approved to treat the disease. Lifestyle modifications aimed at promoting weight loss and weight maintenance remain the current first-line treatment for NAFLD. However, due to the lack of standard and scientific guidance and out-of-hospital supervision, long-term outcomes of lifestyle interventions for patients with NAFLD are often unsatisfactory. In addition, the COVID-19 pandemic aggravated this dilemma. At the same time, digital therapeutics (DTx) are expected to be a new method for the convenient management and treatment of patients with NAFLD and are attracting a great deal of attention. DTx, which provide evidence-based medicine through software programs for remote intervention in preventing, treating, or managing diseases, overcome the drawbacks of traditional treatment. The efficacy of the approach has already been demonstrated for some chronic diseases, but DTx have not been fully developed for NAFLD. This study reviews the concepts, clinical value, and practical applications related to DTx, with an emphasis on recommendations based on unmet needs for NAFLD. A better understanding of the current state will help clinicians and researchers develop high-quality, standardized, and efficient DTx products, with the aim of optimizing the prognosis of patients with NAFLD.

摘要

全球范围内非酒精性脂肪性肝病(NAFLD)的患病率不断增加,令人尤为担忧,因为目前尚无药物被批准用于治疗该疾病。旨在促进减肥和维持体重的生活方式改变仍然是 NAFLD 的当前一线治疗方法。然而,由于缺乏标准和科学的指导以及院外监督,NAFLD 患者生活方式干预的长期效果往往不尽如人意。此外,COVID-19 大流行加剧了这一困境。与此同时,数字疗法(DTx)有望成为一种方便管理和治疗 NAFLD 患者的新方法,引起了广泛关注。DTx 通过软件程序为远程预防、治疗或管理疾病提供循证医学,克服了传统治疗的缺点。该方法已在一些慢性病中证明有效,但 DTx 尚未完全针对 NAFLD 开发。本研究综述了与 DTx 相关的概念、临床价值和实际应用,重点介绍了基于 NAFLD 未满足需求的建议。更好地了解现状将有助于临床医生和研究人员开发高质量、标准化和高效的 DTx 产品,旨在优化 NAFLD 患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc43/10132718/b8952021e5a4/ct9-14-e00575-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc43/10132718/b8952021e5a4/ct9-14-e00575-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc43/10132718/b8952021e5a4/ct9-14-e00575-g001.jpg

相似文献

1
Digital Therapeutics: Emerging New Therapy for Nonalcoholic Fatty Liver Disease.数字疗法:非酒精性脂肪性肝病的新兴新疗法。
Clin Transl Gastroenterol. 2023 Apr 1;14(4):e00575. doi: 10.14309/ctg.0000000000000575.
2
Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping.数字干预结合生活方式教练支持,针对非酒精性脂肪性肝病成年人的饮食和身体活动行为:使用干预映射方法对 VITALISE 进行系统的开发过程。
J Med Internet Res. 2021 Jan 15;23(1):e20491. doi: 10.2196/20491.
3
Exercising in the COVID-19 era: implications in non-alcoholic fatty liver disease (NAFLD).在新冠疫情时代锻炼:对非酒精性脂肪性肝病(NAFLD)的影响。
BMJ Open Gastroenterol. 2021 Jun;8(1). doi: 10.1136/bmjgast-2020-000568.
4
[Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].[非酒精性脂肪性肝病/非酒精性脂肪性肝炎管理概述]
Yakugaku Zasshi. 2019;139(9):1147-1153. doi: 10.1248/yakushi.19-00011-1.
5
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment.非酒精性脂肪性肝病和糖尿病:第二部分:治疗。
Diabetes Metab J. 2019 Apr;43(2):127-143. doi: 10.4093/dmj.2019.0034.
6
Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.基于地中海生活方式的干预对非酒精性脂肪性肝病患者临床特征的改善:一项随机对照临床试验。
Br J Nutr. 2018 Jul;120(2):164-175. doi: 10.1017/S000711451800137X.
7
Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.非酒精性脂肪性肝病应在 2 型糖尿病的标准管理算法中考虑作为治疗分配的因素。
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2233-2239. doi: 10.1016/j.dsx.2020.11.015. Epub 2020 Nov 19.
8
Recent advances in understanding and managing pediatric nonalcoholic fatty liver disease.小儿非酒精性脂肪性肝病的认识与管理的最新进展
F1000Res. 2020 May 19;9. doi: 10.12688/f1000research.24198.1. eCollection 2020.
9
Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.非酒精性脂肪性肝炎(NASH)——当前的治疗建议及未来发展
Z Gastroenterol. 2019 Apr;57(4):508-517. doi: 10.1055/a-0784-8827. Epub 2019 Apr 9.
10
Role of diet and lifestyle changes in nonalcoholic fatty liver disease.饮食和生活方式改变在非酒精性脂肪性肝病中的作用。
World J Gastroenterol. 2014 Jul 28;20(28):9338-44. doi: 10.3748/wjg.v20.i28.9338.

引用本文的文献

1
Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals With Nonalcoholic Fatty Liver Disease: Prospective Single-Arm Feasibility Study.一项改善非酒精性脂肪性肝病患者肝脏脂肪和心脏代谢指标的数字健康计划的长期可行性及结果:前瞻性单臂可行性研究
JMIR Cardio. 2025 Sep 12;9:e72074. doi: 10.2196/72074.
2
Challenges and needs in the management of non-alcoholic fatty liver disease from the perspective of gastroenterology and hepatology specialists: a qualitative study.从胃肠病学和肝病学专家角度看非酒精性脂肪性肝病管理中的挑战与需求:一项定性研究
BMC Gastroenterol. 2025 May 22;25(1):396. doi: 10.1186/s12876-025-03921-z.
3
Evaluating the RESET care program: Advancing towards scalable and effective healthcare solutions for metabolic dysfunction-associated liver disease.
评估RESET护理计划:迈向针对代谢功能障碍相关肝病的可扩展且有效的医疗保健解决方案。
World J Hepatol. 2025 Apr 27;17(4):105254. doi: 10.4254/wjh.v17.i4.105254.
4
Effectiveness of RESET care program: A real-world-evidence on managing non-alcoholic fatty liver disease through digital health interventions.RESET护理计划的有效性:通过数字健康干预措施管理非酒精性脂肪性肝病的真实世界证据。
World J Hepatol. 2025 Jan 27;17(1):101630. doi: 10.4254/wjh.v17.i1.101630.
5
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic.下一代抗病毒药物与肥胖流行时代的肝癌预防
Hepatology. 2025 Jan 14. doi: 10.1097/HEP.0000000000001227.
6
From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome - current insights and future directions.从肥胖到脂肪变性:代谢功能障碍相关脂肪性肝病,代谢综合征的肝脏表现——当前见解与未来方向
Clin Diabetes Endocrinol. 2024 Dec 2;10(1):39. doi: 10.1186/s40842-024-00187-4.
7
Digital therapeutics lead to clinically significant body weight loss in patients with metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.数字疗法可导致代谢功能障碍相关脂肪性肝病患者的体重出现有临床意义的下降:系统评价和荟萃分析。
Hepatol Commun. 2024 Jul 31;8(8). doi: 10.1097/HC9.0000000000000499. eCollection 2024 Aug 1.
8
Extract Exerts Protective Effects against Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis in Mice.提取物对蛋氨酸和胆碱缺乏饮食诱导的小鼠非酒精性脂肪性肝炎具有保护作用。
Foods. 2024 Jul 1;13(13):2101. doi: 10.3390/foods13132101.
9
How to Enhance Adherence in Patients with Nonalcoholic Fatty Liver Disease: A Thought-Provoking Issue.如何提高非酒精性脂肪性肝病患者的依从性:一个发人深省的问题。
J Med Internet Res. 2024 May 14;26:e59208. doi: 10.2196/59208.
10
Telemedicine as an Option for Monitoring Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Patients Facing the COVID-19 Pandemic: A Systematic Review and Meta-Analysis.远程医疗作为监测面临2019冠状病毒病大流行的代谢功能障碍相关脂肪性肝病(MAFLD)患者的一种选择:系统评价与荟萃分析
J Pers Med. 2024 Mar 2;14(3):281. doi: 10.3390/jpm14030281.